Ulceration of Steroid-Induced Striae Distensae in a Patient with a Rare Brain Tumor on Bevacizumab

Eleni Pilitsi, Stephanie Wang, Marylee Braniecki and Maria Lina Tsoukas

Department of Medicine, Democritus University of Thrace, Greece
Department of Dermatology, University of Illinois at Chicago, USA
Department of Pathology, University of Illinois at Chicago, USA

^*Correspondance to: Maria Lina Tsoukas 

 PDF  Full Text Case Report | Open Access

Abstract:

Bevacizumab, a Vascular Endothelial Growth Factor (VEGF) inhibitor, is approved for recurrent glioblastoma and various metastatic cancers. VEGF plays an important role in angiogenesis and wound healing and thus, the use of Bevacizumab has been associated with dehiscence, ecchymosis, surgical site bleeding, and wound infection. A unique side-effect of Bevacizumab is the ulceration of steroid-induced striae distensae in patients treated for brain tumors, mainly glioblastoma. Here we report for the first time the case of a young female who presented with ulcerated striae while on treatment with Dexamethasone and Bevacizumab for anaplastic hemangiopericytoma, a rare malignancy of the central nervous system.

Keywords:

Cite the Article:

Pilitsi E, Wang S, Braniecki M, Tsoukas ML. Ulceration of Steroid-Induced Striae Distensae in a Patient with a Rare Brain Tumor on Bevacizumab. Clin Oncol. 2019; 4: 1619.